CIK 0001754068
- Non-accelerated filer
- Smaller reporting company
Kalaris Therapeutics, Inc.
Sign in to watch- Ticker
- KLRS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831971007
- Phone
- +1 650-249-2727
- Business address
- 400 CONNELL DRIVE, SUITE 5500, BERKELEY HEIGHTS, NJ, 07922
- Former names
- Allovir, Inc., ViraCyte, Inc.
- 4 Open-market sale Chief Commercial Officer sold 515 shares at $3.63 ($1,871)
- 4 Grant or award Atillasoy Ercem acquired 14,000 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 48,125 shares (grant or award)
- 4 Open-market sale Director sold 65,725 shares at $3.67 ($241,106)
- 4 Open-market sale Chief Executive Officer sold 29,135 shares at $4.33 ($126,257)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Chief Commercial Officer sold 15,262 shares at $4.40 ($67,167)
- 4 Open-market buy Director bought 5,000 shares at $4.64 ($23,197)
- 4 Open-market sale Director sold 4,227 shares at $5.87 ($24,812)
- 4 Open-market sale Director sold 1,162 shares at $6.68 ($7,767)
- 4 Open-market sale Chief Commercial Officer sold 852 shares at $6.68 ($5,695)
- 4 Open-market sale Atillasoy Ercem sold 2,040 shares at an average $6.04 ($12,329)
- 4 Open-market sale Chief Accounting Officer sold 276 shares at $6.68 ($1,845)
- 4 Grant or award Chief Accounting Officer acquired 17,442 shares (grant or award)
Page 12 of 19 · 363 filings